Home > Journals > Minerva Cardiology and Angiology > Past Issues > Minerva Cardiology and Angiology 2021 October;69(5) > Minerva Cardiology and Angiology 2021 October;69(5):525-32

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ORIGINAL ARTICLE   

Minerva Cardiology and Angiology 2021 October;69(5):525-32

DOI: 10.23736/S2724-5683.20.05413-4

Copyright © 2020 EDIZIONI MINERVA MEDICA

language: English

Targeting “diabetic” coronary artery disease merging the properties of sirolimus coated balloon with sirolimus eluting stent

Luca TESTA 1 , Matteo CASENGHI 1, Antonio POPOLO RUBBIO 1, Sameer DANI 2, Devang DESAI 3, Rashmit PANDYA 2, Pritesh PAREKH 4, Nirav BHALANI 5, Arvind SHARMA 5, Chirag SETH 5, Francesco BEDOGNI 1

1 Department of Cardiology, IRCCS San Donato Polyclinic, Milan, Italy; 2 Life Care Institute of Medical Sciences and Research, Apollo Hospitals, Ahmedabad, India; 3 Mahavir Hospitals, Surat, India; 4 Care Hospitals, Surat, India; 5 Rhythm Heart Institute, Baroda, India



BACKGROUND: Patients with diabetes mellitus (DM) represents a challenging subset of population as they experience worse outcomes after percutaneous coronary intervention than patients without diabetes. We evaluated the 2-year efficacy and safety profile of the Abluminus DES+ in patients with diabetes within the population enrolled in the large multicenter en-ABL e-registry.
METHODS: Multicenter, prospective, all-comers registry performed in 31 centers in India. We analyze patients according to the diagnosis of DM and insulin dependency (ID or Non-ID): non-DM (1641 patients), NIDDM (721 patients), IDDM (138 patients). The primary endpoint was a composite of device-oriented major adverse cardiac events (MACE): cardiac death, target vessel-related myocardial infarction (MI), and ischemia-driven target lesion revascularization (TLR)/ target vessel revascularization (TVR) at 2-year. Stent thrombosis (ST) at any time point was also recorded.
RESULTS: The MACE rate at 2-year follow-up was 3.0% in the overall population with DM patients showing a higher rate of primary endpoint compared to non-DM (4.4% vs. 2.4%, P=0.025). Rate of cardiac death was actually low and consistent between the 2 groups (1.7% vs. 0.9%, P=0.100). At 2-year follow-up, the rate of ST was 0.9% in DM patients versus 0.5% in non-DM, P=0.213.
CONCLUSIONS: At 2-year follow-up, the Abluminus DES+ technology that merges the features of a sirolimus coated balloon with those of a bioresorbable polymer drug eluting stent appears to be safe and effective. This safety/efficacy profile was consistent in patients with or without DM.


KEY WORDS: Diabetes mellitus; Drug-eluting stent; Stents

top of page